Breast Cancer Symposium | Conferences

Veliparib Demonstrates Clinical Activity in Patients with BRCA-Positive Breast, Ovarian Tumors

September 06, 2014

The poly (ADP-ribose) polymerase (PARP) inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA-wild type tumors.

LH-RH Analog as Adjuvant to Chemotherapy May Preserve Fertility in Younger Breast Cancer Patients

September 05, 2014

Long-term follow-up of a phase III clinical trial shows strong trends toward a greater likelihood of resuming menses and becoming pregnant when a luteinizing hormone-releasing hormone (LH-RH) analog is administered with chemotherapy in patients with breast cancer.